Foghorn Therapeutics Inc.

NasdaqGM:FHTX 株式レポート

時価総額:US$459.2m

Foghorn Therapeutics 過去の業績

過去 基準チェック /06

Foghorn Therapeuticsの収益は年間平均-12.9%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間19% 76.2%割合で 増加しています。

主要情報

-12.9%

収益成長率

46.1%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率76.2%
株主資本利益率n/a
ネット・マージン-245.7%
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk

Oct 22
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up

Sep 01
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up

Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking

Jul 17
Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

May 09
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth

Apr 12
Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too

Feb 22
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth

Dec 13
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth

Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues

Nov 07
Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues

Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

Jun 14
Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

Foghorn Therapeutics: Selling For Less Than Cash Value

Oct 10

Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286

Aug 23

Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M

Aug 09

Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity

Jun 02

We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

Apr 13
We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?

Feb 27
Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?

収支内訳

Foghorn Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGM:FHTX 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 2435-8630-10
31 Mar 2434-93310
31 Dec 2334-98320
30 Sep 2333-1033359
30 Jun 2322-1153359
31 Mar 2321-112320
31 Dec 2219-109310
30 Sep 2216-109290
30 Jun 229-109270
31 Mar 225-105240
31 Dec 211-101220
30 Sep 211-93200
30 Jun 211-85170
31 Mar 211-78140
31 Dec 200-69110
30 Sep 200-6380
30 Jun 200-588-20
31 Mar 200-547-10
31 Dec 190-5170

質の高い収益: FHTXは現在利益が出ていません。

利益率の向上: FHTXは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: FHTXは利益が出ておらず、過去 5 年間で損失は年間12.9%の割合で増加しています。

成長の加速: FHTXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: FHTXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -2.3% ) と比較することは困難です。


株主資本利益率

高いROE: FHTXの負債は資産を上回っているため、自己資本利益率を計算することは困難です。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘